BioNTech reports high efficacy of COVID-19 vaccine
Interim data on BioNtechs/Pfizers COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1280 entries already.
Entries by Thomas Gabrielczyk
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
/in News/by Thomas GabrielczykSwiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedicas experimental kidney drug ANG-3777.
Cell and gene therapy specialist Minaris expanding
/in News/by Thomas GabrielczykJapanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.
Protein Brewery raise 22m in Series A
/in News/by Thomas GabrielczykLead investor Novo Growth has led a 22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
Galecto raise US$85m in Nasdaq IPO
/in News/by Thomas GabrielczykHBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
BI initiates Phase II testing of COVID-19 drug
/in News/by Thomas GabrielczykBoehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
3P Bio to manufacture SpyBiotech vaccine
/in News/by Thomas GabrielczykBritish SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.
Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
/in News/by Thomas GabrielczykSwedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region
Transgene reports clinical results of TG4001 plus avelumab
/in News/by Thomas GabrielczykTransgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaAs PD-L1 blocker avelumab.
Roche licences antiviral nucleoside from Atea
/in News/by Thomas GabrielczykRoche AG has paid US$350 in cash to co.develop and market Atea Pharmaceuticals oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.